Clinical Trial: Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07536789) titled 'Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma' on April 11.

Brief Summary: This study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).

Study Start Date: April 15

Study Type: INTERVENTIONAL

Condition: Hepato Cellular Carcinoma (HCC)

Intervention: DRUG: MRG003

MRG003 will be administered by IV, 2.3 mg/kg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Fudan ...